Myra Vision, A Shifamed Portfolio Company, Closes $25M In Series B Financing
06/26/23, 2:09 PM
Location
campbellMoney raised
$25 million
Industry
biotechnology
health care
Round Type
series b
Investors
Shifamed Angel Investors, Pa Med Tech Vc Fund, The Capital Partnership, Cormorant Asset Management
Myra Vision, a Shifamed portfolio company, announced today the closing of its $25M Series B financing. Led by Cormorant Asset Management, with significant participation from The Capital Partnership (TCP), the PA MedTech VC Fund and Shifamed angel investors, the funds will be used to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's CalibreyeTM System, a novel treatment that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.
Company Info
Location
campbell, kentucky, united states
Additional Info
Myra Vision, a privately held portfolio company of Shifamed LLC, is developing a novel technology that is designed to allow safe outflow control to achieve maximum reduction of intraocular pressure (IOP) while also reducing complexity and complication rates. To learn more about Myra Vision, please visit www.myravision.com.